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Abstract
Pancreatic neuroendocrine neoplasms (P-NENs) are the second most common solid pancreatic neoplasms. P-NENs have a wide
range of imaging features presentations and they can be detected with typical and atypical imaging presentations. Typical and
atypical appearances can be explained by pathologic correlations. P-NENs are generally hypervascular lesions, showing a typical
enhancement behavior after contrast media injection during imaging methods, but they could also have different imaging
features, creating some difficulty in differential diagnosis. For this reason, radiologists should be aware of different imaging
presentations of these neoplasms. Radiological evaluation has a critical role in P-NENs identification, characterization, and
staging of these neoplasms, especially in those cases in which surgery is the treatment of choice. The present paper shows,
indicating the underlying pathologic correlations, typical and atypical presentations of NENs.
Key Points
• P-NENs have a wide range of imaging features presentations, typical and atypical.
• Pathology could help in better understanding the typical P-NENs appearance at imaging.
• P-NENs are generally hypervascular lesions.
• Radiological evaluation has a critical role in P-NENs identification and management.
• Radiologists should know every type of different imaging presentation of P-NENs to better diagnose these kinds of lesions.
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Abbreviations
NEN Neuroendocrine neoplasm
P-NEN Pancreatic neuroendocrine neoplasm
RFA Radiofrequency ablation
Introduction
Pancreatic neuroendocrine neoplasms (P-NENs) have a wide
range of imaging features presentations. They can show dif-
ferent typical and atypical, common and uncommon, rare and
very rare imaging presentations. Typical appearances can be
explained by pathologic correlations and multimodalities ap-
proaches (US, CT, MRI, EUS, and PET) can be used to better
show these features.
A radiologist has to know every possible imaging presen-
tations range to improve the diagnosis and, therefore, manage-
ment and treatment of P-NENs.
P-NENs are the secondmost common solid pancreatic neo-
plasms, after the first pancreatic ductal adenocarcinoma.
Nevertheless, they are rare neoplasms, accounting for 1–2%
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of all pancreatic lesions [1]. Even though they are rare tumors,
in the last 20–30 years, their incidence has significantly in-
creased more than twice, due to diagnostic imaging improve-
ments and to medical knowledge increase [2–4]. Most of the
time, they are sporadic tumors and they are solitary, whereas
sometimes they are part of hereditary syndromes, such as
multiple endocrine neoplasia type 1 (MEN1), Von Hippel–
Lindau (VHL), neurofibromatosis type 1 (NF1), and tuberous
sclerosis complex (TSC), and, in these hereditary syndromes,
they present more frequently as multifocal lesions [1].
P-NENs can be divided into two categories, based on pa-
tients’ symptoms complained: functioning, if they produce
and release hormones with different syndromes, depending
on the produced molecule type, and non-functioning, in case
of tumors inactivity. Non-functioning lesions are more fre-
quent than functioning ones, accounting for two-thirds of all
P-NENs [1, 2, 5–7]. However, in recent years, the small non-
functioning lesions have been diagnosed incidentally with in-
creased frequency in asymptomatic patients, due to imaging
techniques improvements.
Pathology
The typical P-NEN is rich in small vessels with high cellular-
ity and poor fibrotic stroma (Fig. 1), usually giving a homog-
enous macroscopic appearance, with, in most cases, a greater
consistency than the adjacent pancreatic parenchyma.
Calcifications and necrosis can be present, especially in large
masses [1, 2]. A rich vascularization is typical of the large
majority of P-NENs, as previously stated, and it is responsible
for the hypervascular typical aspect in imaging studies with
contrast media. The majority of P-NENs present as a solitary,
solid, delineated mass with a rounded or multilobulated
margins and a sharp delimitation from the surrounding paren-
chyma; sometimes, there could be the presence of a fibrotic
pseudo-capsule that partially or entirely surrounds the tumor;
they are rarely encapsulated. P-NENs very often show expan-
sive growth pattern with compression of adjacent structure,
such as the main pancreatic and/or biliary ducts (Fig. 2).
However, depending on the aggressiveness, P-NENs can
grossly show features of malignancy with evident invasive
growth pattern infiltrating adjacent ducts, structures, and or-
gans [1, 8].
The tumor grade is one of the most important prognostic
factors of neuroendocrine tumors, underlying the importance
of knowing this data, by means of histological analysis. With
increase of the tumor grade, the prognosis is lower.
In the 2017, the NENsWHO classification was revised and
NENs have been classified according to the ENETS grading
system, which is based on the proliferative activity of the
neoplasm:
– NEN G1: Ki67 < 3% and/or < 2/10 mitosis 10/HPF; well
differentiated
– NEN G2: Ki67 > 3% and < 20% and/or 2–20 mitosis 10/
HPF; well differentiated
– NEN G3: Ki67 > 20% and/or > 20 mitosis 10/HPF; well
differentiated
– NEC (neuroendocrine carcinoma) G3 small cells: Ki67 >
20% and/or > 20 mitosis 10/HPF; poorly differentiated
– NEC G3 large cells: Ki67 > 20% and/or > 20 mitosis 10/
HPF; poorly differentiated
P-NENs classification
The most common characteristic of P-NENs is that, generally,
they are hypervascular, showing a typical enhancement be-
havior after contrast media injection during several imaging
methods (Fig. 3).
As previously stated, these neoplasms are mainly
subdivided into two large groups (functioning and non-func-
tioning), with different main features.
Functioning P-NENs are usually diagnosed in younger pa-
tients compared to the non-functioning P-NENs (55 years vs.
59 years), and the first type are usually smaller in dimension
(< 3 cm) and usually non-metastatic at the time of diagnosis.
However, the non-functioning neoplasms are generally the
majority of P-NENs, accounting for about 40–90% of cases
[2, 9]. Usually, functioning P-NENs present early with clinical
manifestations related to the produced hormones, so, often,
patients with P-NENs undergo imaging studies with a strong
suspicion of disease.
Insulinomas are the most common functioning P-NENs
and they account for about 60% of these neoplasms.
Fig. 1 Pancreatic neuroendocrine neoplasm (P-NEN). Histological
analysis: neuroendocrine neoplasm (NEN) showing high cellularity dur-
ing hematoxylin and eosin staining and high intralesional vascular net-
work demonstrated by CD34 immunohistochemical staining
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Fig. 2 Capsulated NEN. MRI
study: the pancreatic head lesion
is slightly hypointense on T1-
weighted fat-saturated axial im-
ages (a) and presents diffusion
restriction (b) on DWI (b = 800).
In the late hepatospecific phase
(c) with contrast medium (Gd-
BOPTA), the common bile duct
(C) is clearly visible and not di-
lated, since it is displaced but not
compressed by the pancreatic
head mass
Fig. 3 Non-functioning NEN. US
and CEUS examinations: large
hypoechoic mass (a) with small
calcifications in the pancreatic
head, causing upstream dilation of
the Wirsung duct. This lesion is
inhomogeneously
hypervascularized at CEUS (b).
CT examination: the pancreatic
mass appears inhomogeneously
hyperenhancing (c) in respect to
the surrounding pancreatic
parenchyma on dynamic phases.
Dynamic MRI: inhomogeneous
hypervascularity (d) of the
pancreatic head mass
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Insulinomas are slightly prevalent in middle-aged (V–VI de-
cades) women, and they are usually ubiquitarian within the
gland, maybe with a slight prevalence in the body-tail.
Usually, they have a benign course and behavior (85–99%)
and they are often small (Fig. 4), smaller (90%< 2 cm) than
other types. However, they can also be bigger and they could
have a malignant behavior in some cases. At the time of clin-
ical presentation, about half of cases are smaller than 1.5 cm
[1, 7]. Insulinomas are usually solitary, but they could be
multifocal in the majority of patients with MEN1 disease.
The second most common type of functioning P-NENs are
gastrinomas, accounting for about 20% of cases. Gastrinomas
are slightly prevalent in middle-aged (V decade) men and they
are usually located in the Bgastrinoma triangle^, defined as the
anatomical area among the junction of the cystic duct and
common bile duct, the second and third duodenal portions,
and the pancreatic head and neck. They tend to have a malig-
nant course, accounting for about 60–65% of cases, and they
are often multiple (about 60% cases, of which 20–60% in
MEN1 disease) [1, 10].
Other his to logica l types are somatos t inomas,
glucagonomas, ACTH-omas, and VIP-omas, accounting for
a small percentage of P-NENs, about 20%, and their behavior
can be atypical as a rule, so they tend to be bigger, malignant,
and metastatic at diagnosis most of the time [1, 7, 10–12].
Non-functioning NENs account for the majority of P-
NENs. They tend to be larger (Fig. 5) than functioning ones,
ranging from 1 to 20 cm in diameter, and they usually show a
higher malignancy rate, up to 90%, with infiltration of retro-
peritoneal structures, causing pain and other symptoms due to
mass effect at the time of presentation. As a consequence, they
are more often diagnosed at an advanced stage than function-
ing tumors. Non-functioning lesions frequently have an inho-
mogeneous aspect mainly due to necrotic areas and calcifica-
tions. They are predominantly characterized by an expansive
growth pattern; therefore, they are usually clinically silent
until adjacent viscera and structures are involved [1, 7].
As previously stated, small non-functioning P-NENs are
being incidentally discovered with increasing frequency in
asymptomatic patients, due to recent advances in imaging
methods and an increasing number of imaging abdominal
scans and studies [1, 13, 14].
Typical imaging presentations
During imaging, P-NENs usually present as a solid
hypervascular mass (Fig. 3).
During US, P-NENs are usually well-marginated
hypoechoic masses with sharp margins, more or less homo-
geneous due to their size, which can vary. Doppler study could
show small vessels within lesions. These neoplasms typically
appear hypervascular (Fig. 3) during contrast-enhanced ultra-
sound (CEUS), and they usually show a rapid and intense
enhancement in the early contrast-enhanced phase [1, 15,
16]. In bigger lesions, such as non-functioning types, necrotic
intralesional areas can be seen within the rapid intense en-
hancement in the early dynamic phase at CEUS. Non-
functioning P-NENs usually have a larger size than function-
ing P-NENs, which also justifies their tendency to contain
Fig. 4 Insulinoma. CT: a small
insulinoma appearing as a
hypervascular hyperdense nodule
(a) in the pancreatic head. MRI:
the small insulinoma is well
detectable as a hyperintense
nodule (b) on T2-weighted coro-
nal images and hypervascular (c)
in the dynamic phase
946 Insights Imaging (2018) 9:943–953
necrosis and hemorrhage, giving them a typical presentation at
imaging before and after contrast injection. Small calcifica-
tions, central necrotic or hemorrhagic, or cystic degeneration
can be better identified during ultrasound harmonic imaging
within P-NENs [1, 6, 17].
During CT, P-NENs typically present as more or less ho-
mogeneously isodense or slightly hypodense, well-defined
masses during the pre-contrast phase, but they can also be
inhomogeneous if larger. After contrast injection, during the
arterial phase, they tend to be homogeneous or inhomoge-
neous hyperdense (Fig. 3), generally well depictable with re-
spect to the adjacent parenchyma, and hyperdense or isodense
during the portal phase, due to their vascularization. Very
small intralesional calcifications can be presented in particular
in the largest non-functioning lesions, which can also be in-
homogeneous (Fig. 5), due to the presence of hypodense ne-
crotic areas [1, 14, 18–20].
At MRI, they usually present as well-defined rounded le-
sions, homogeneously hypointense on T1-weighted sequence
and hyperintense on T2-weighted sequence, better visualized
with fat-suppression techniques. In case of bigger dimensions,
they could be more inhomogeneous.
Diffusion-weighted imaging (DWI) may be useful in the
study of P-NENs because, usually, they have clear restriction
signal during DWI (Fig. 2) due to the high cellularity. DWI
may help in the detection of P-NENS, especially for localizing
non-hypervascular neoplasms [21]. It has been reported that
P-NENs with different grades of differentiation can be distin-
guished evaluating ADC maps: poor-differentiated P-NENs
have significantly lower mean ADC values compared to nor-
mal pancreatic tissue and to well-differentiated pancreatic
neuroendocrine tumors [22–24]. DWI MR could predict pan-
creatic neuroendocrine tumor grade, as reported in the litera-
ture, playing a role in tumor prognostic stratification at the
beginning of the clinical history of the patient [25]. After
intravenous contrast administration, they typically appear
hypervascular (Fig. 3) during the arterial phase and isointense
or slightly hyperintense during the portal phase, more or less
homogeneous related with their dimensions [1, 18, 19, 26].
Imaging methods can have a role in the detection, charac-
terization, and staging of P-NENs. The staging of these tumors
is important to choose the better treatment plan.
Metastases from P-NENs tend to resemble imaging fea-
tures of primary tumors, usually showing enhancement after
contrast media injection.
Atypical imaging presentations and variants
P-NENs could show atypical behavior. The most common
atypical presentations are the hypoenhancing pattern, the
intravessels growth, the intraductal growth, and the cystic
and calcified variants [22].
P-NENs sometimes appear hypovascular (Fig. 6) after con-
trast media injection and/or with progressive enhancement in
the portal and late phases, causing some problems in differen-
tial diagnosis, mimicking ductal adenocarcinoma [1].
Actually, hypovascular P-NENs are not so rare, reaching
49% in a group of patients with NENs in the clinical records
of Jeon et al. [27]. This appearance is directly related to the
amount of dense and hyalinized stroma within the tumor, and
to the small lesion dimension or of its vascular network [22,
28, 29]. It is crucial to carefully evaluate all the other imaging
characteristics (size, margins, growing pattern, and main pan-
creatic duct aspect) in order to carry out an accurate differen-
tial diagnosis and to differentiate them from ductal adenocar-
cinoma, because these two entities may have a completely
different management and, last but not least, a completely
different prognosis [22].
In this variant, the involvement of the main pancreatic
duct is more frequent, with also the presence of the Bdouble-
duct sign^ if there is a concomitant involvement of the com-
mon bile duct due to a lesion occurring in the pancreatic
head. This tumor variant at imaging is very close to the
expected picture of a ductal adenocarcinoma, especially if
it is small in dimension, implicating the cytological or his-
tological confirmation mandatory in every case [1]. At im-
aging, these fibrous P-NENs have atypical features,
appearing hypovascular in the arterial phase at CT and
MRI and with a possible progressive enhancement in the
other phase due to the presence of fibrosis within lesions,
except during CEUS due to the microbubble contrast media
inner characteristics. Moreover, during MRI, it could lack
the typical high hyperintensity on T2-weighted images,
appearing isointense or slightly hyperintense on T2-
weighted sequences, and, also, the strong restriction on
Fig. 5 Non-functioning NEN. CT examination: huge inhomogeneously
hypervascular pancreatic body-tail mass with necrotic areas and
intralesional calcifications. Liver metastatic involvement is present
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DWI could be missed, causing mistakes in the differential
diagnosis.
The intraductal growing and the intravessels growing are
characterized by a colonization of their lumen with an
endoluminal neoplastic cells growth. This growth type is a
typical characteristic feature of P-NENs (Fig. 7) and they are
very rare.
Intraductal location and growth of P-NENs may occur in
two different scenarios. First, as part of a parenchymal pan-
creatic lesion strictly next to the main pancreatic duct that
extends into the pancreatic duct and then grows along it, so
the intraductal growth is connected to an extraductal lesion [1,
30, 31]. Second, the rarer setting of a NEN that originates
within the main duct, fills the lumen as a polypoid mass, and
grows along the duct. This type of lesion does not have a
parenchymal component [32]. Usually, this behavior is shown
by non-functioning neoplasms that could grow within the
main pancreatic duct and may completely obstruct the lumen,
causing an obstructive pancreatitis.
The intraductal growth could be very insidious at im-
aging because it could be small in dimension and could be
masked by pancreatitis signs. In case of an intraductal
lesion associated with intrapancreatic lesion, at imaging,
it could be possible to see the intrapancreatic one.
Whereas in the case of a lesion that is exclusively
intraductal, this is very difficult to observe at imaging;
in the majority of these cases, diagnosis is possible only
after surgery. At US, lesions may appear hyperechoic and
difficult to separate from adjacent pancreatic parenchyma.
At CT, often, these lesions are not visible. MR could be
useful due to cholangiopancreatography (MRCP) because
it could be possible to see a filling defect because lesions
could appear hypointense compared to surrounding fluid
and it could be possible to see them enhance following
the administration of contrast agent.
In case of vessels involvement, this particular growing pat-
tern is usually confined to peri-pancreatic vessels, such as
splenic and portal veins, producing a neoplastic thrombus,
characterized by enhancement during contrast media imaging
studies, quite the opposite of blood clot thrombus [33].
P-NENs may also present as a lesion growing around the
main pancreatic duct, causing abrupt-type stricture with up-
stream dilatation and a normal-caliber duct downstream of the
stricture [1, 34, 35]. These neoplasms are usually positive
using serotonin and very small in dimensions, exhibiting high-
ly f ibrot ic s t roma, and, as a consequence, poor
vascularization.
In 5–10% of cases, P-NENs could present a cystic degen-
eration, usually in non-functioning lesions, causing some dif-
ficulties in differential diagnosis. Usually, cystic NENs are
larger, more often symptomatic, and more likely to be non-
functional than solid NENs [36].
They present as a well-circumscribed cystic lesion, both
unilocular and multilocular, usually with inner septa, with
smooth margins and peripheral enhancement, usually on both
arterial and portal phases, according to the hypervascular na-
ture of P-NENs [37, 38]. The cyst is usually unilocular, in the
center of the lesion, sometimes with septa, without enhance-
ment post-contrast media injection, surrounded by a rim of
neoplastic tissue hypervascular at imaging (Fig. 8).
During US, neuroendocrine cystic neoplasms are anechoic
lesions delimited by a wall of variable thickness. In case of
contrast media injection, this wall and eventual inner septa
show enhancement.
During CT, usually, the cystic portion is hypodense, with
wall and septa enhancement after contrast media injection.
CT is the most common initial imaging study in the evalu-
ation of patients with cystic pancreatic lesions, whereas the
gold standard in studying pancreatic cystic lesions is MR, due
to its superior fluid and soft-tissue contrast, and it affords the
best non-invasive means for the morphologic evaluation of
cystic lesions of the pancreas. The MR signal is typically
low in T1-weighted sequences, and high in T2-weighted se-
quences, with enhancement of wall and septa in post-
contrastographic phases.
Calcifications may occur in P-NENs, unlike intra-tumor
calcifications, which are not often seen in ductal adenocarci-
noma. More commonly, calcifications occur within non-
functioning and larger neoplasms [22, 38]. However,
insulinoma may contain calcifications in up to 20% of cases.
Fig. 6 Non-functioning NEN. CT
examination: huge
inhomogeneously hypovascular
pancreatic body-tail mass with
necrotic areas and intralesional
calcifications studied in the pan-
creatic (a) and venous (b) phases
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Overall, calcifications can be found in NENs in up to 16% of
cases; these calcifications tend to be focal, coarse, irregular,
and centrally located [22, 39].
A summary of the typical and atypical presentations of P-
NENs is included in Table 1.
Nuclear medicine techniques
The majority of P-NENs (about 70%), with the exception of
insulinomas and poorly differentiated neoplasms, are usually
characterized by lots of somatostatin receptors (SSRs) along
the cell membrane, and this is the reason why functional im-
aging with somatostatin analogs is able to clearly show these
neoplasms [40–42].
Somatostatin receptor scintigraphy (SRS), also called
OctreoScan due to the first commercially available somato-
statin analog called Octreotide, is based on the high affinity of
synthetic somatostatin analogs for tissue expressing SSRs,
such as most NENs.
This technique gives a scan of the whole body, allowing the
detection of primitive tumor and metastatic lesions. Moreover,
SRS gives functional information based on SSRs expression
by the tumor, also contributing to the correct selection pa-
tients’ therapy with somatostat in analogs and/or
radiometabolic therapy [2, 43]. Nevertheless, SRS has the
intrinsic limit of basing itself only on the tumor SSRs expres-
sion. Non-specific uptake in inflammatory tissue or normal
organs and poor intrinsic spatial resolution are two recognized
limitations of SRS. Often, poorly differentiated NENs and
insulinomas are not identified during SRS, and it does not give
anatomical or surgical resectability information [2, 44].
Fused positron emission tomography (PET)/computed to-
mography (CT) is a recent imaging technique that provides
functional information for PET study and anatomic details for
CT study. PET/CT provides help in depicting pancreatic tu-
mors and distant metastases, in performing pre-operative stag-
ing, and in monitoring treatment response [40].
A new PET tracer, 68Ga-DOTATATE, a new somatostatin
analog combined with gallium (with other somatostatin ana-
logs labeled with gallium), was recently introduced to nuclear
medicine in the NENs study, and several investigations
showed that it has greater sensitivity than OctreoScan in de-
tecting P-NENs, in particular the small ones [45–47]. As a
consequence, PETwith gallium could be used in tumor detec-
tion and staging, and in selecting the correct treatment and
therapy for patients.
Another radiopharmaceutical used in PET imaging is
fluorodeoxyglucose (FDG), because, usually, tumoral cells
have high glucose metabolism, and, as a consequence, they
show FDG uptake. Generally, well-differentiated, slow-
growing NENs demonstrate little or no FDG uptake, due to
their low metabolic activity, whereas poorly differentiated
NENs and metastases from P-NENs, which rarely express
somatostatin receptors, are well depicted during FDG-PET.
For the depiction of P-NENs, FDG PET has a sensitivity of
53–57% [40, 41, 48–50]. For these reasons, FDG PET/CTcan
play a role in discerning well- and poor-differentiated neo-
plasms because, with the increase in aggression and
Fig. 7 Non-functioning NEN. CT
examination: small hypervascular
pancreatic head mass irregular in
shape invading the superior
mesenteric vein with a small
neoplastic thrombus studied in the
pancreatic (a) and venous (b)
phases
Fig. 8 Cystic NEN. CT examination: small cystic exophytic pancreatic
tail mass with hypodense central area surrounded by thick hypervascular
rim
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malignancy potential of the tumor, there is an increase in the
glucose uptake by the neoplasm. FDG activity on PET is
related to tumor progression and increased mortality [45, 51,
52].
Kayani et al. [42] reported that high-grade and poor-
differentiated NENs show greater FDG uptake, whereas
low-grade and well-differentiated tumors demonstrate greater
68Ga-DOTATATE uptake.
Interventional radiology
Imaging methods, such as transabdominal ultrasound, endo-
scopic ultrasound, and CT, can also be used to guide fine
needle aspiration or fine needle biopsy for cytological and/or
histological confirmation of P-NENs.
Moreover, in NENs, interventional radiology could play an
important role, especially in the control of non-surgical cases
of disease.
Local treatment strategies such as embolization,
chemoembolization, and targeted radionuclide therapy are in-
creasingly being used in case ofmetastatic liver disease; more-
over, local ablative techniques such as radiofrequency ablation
(RFA) and cryotherapy are also important tools [53, 54].
Usually, in case of P-NENs, the most relevant use of inter-
ventional radiology is for liver metastases treatment.
Indications for imaging-guided RFA have been reported [53,
55]. During imaging after local ablative treatment, the ablation
area (Fig. 9) has to be typically hypodense, with no enhance-
ment during dynamic phases due to coagulative necrosis.
P-NENs treatment
P-NENs treatment should be individualized for every patient
and planned by a multidisciplinary group.
The first treatment for P-NENs is radical surgery, and in
patients with advance disease and/or metastatic disease, a mul-
tidisciplinary approach should be linked to surgical methods
[2].
Surgery is the treatment of choice for both primary tumors
andmetastatic lesions if eradicable, and this is why differential
diagnosis with pancreatic ductal adenocarcinoma is very im-
portant, due to the completely different treatment choice and
consequent prognosis.
In case of functioning neoplasms, surgery should be man-
datory due to the symptoms complained by patients, also in
case of small lesions, whereas in case of small (< 2 cm) non-
functioning neoplasms well differentiated and with a low
grade, nowadays it is possible to use a Bwait and watch^
follow-up, in order to avoid mortality and surgery complica-
tions in patients with lesions with a very low malignancy rate.
In some cases, for example in local advanced disease, it
should be useful to follow a Bneoadjuvant therapy^ with so-
matostatin analogs and/or metabolic radiotherapy to down-
stage the disease and then apply surgery.
In case of metastatic disease, there are several possibilities,
such as chemotherapy, therapy with somatostatin analogs,
metabolic radiotherapy, and local treatment, the latter with
interventional radiology, such as RFA and trans-arterial
chemoembolization.
Conclusions
Pancreatic neuroendocrine neoplasms (P-NENs) are typically
hypervascular, but they could present with atypical features.
At imaging, the atypical presentations of P-NENs are less
frequent than typical presentations, but they could be very
heterogeneous and hard to characterize, because of peculiar
pathological changes, causing possible misdiagnosis. As a
consequence, it is very important for radiologists to know all
of the possible P-NENs presentations forms.
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